---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-021541"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:00:41.324265+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Ocular Therapeutix makes slides with SOL-1 Phase 3 results for AXPAXLI in wet AMD available at Macula Society

## Summary
- Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.
- Presentation covers detailed results from SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI).
- AXPAXLI is being developed for treatment of wet age-related macular degeneration (wet AMD).
- Filing does not disclose the actual trial outcomes or numerical results.

## SEC filing metadata
- accession: 0001104659-26-021541
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/0001104659-26-021541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/tm267471d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-021541
- JSON: https://secwatch.observer/filing/0001104659-26-021541.json
- Plain text: https://secwatch.observer/filing/0001104659-26-021541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.